Product Description
An immunocytokine of the human monoclonal antibody fragment F16 (scFv) against the extra-domain A1 of tenascin-C fused, via a short 5-amino acid linker, to a recombinant form of the human cytokine interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. The monoclonal antibody portion of the F16-IL2 fusion protein binds to tumor cells expressing the tumor associated antigen (TAA) tenascin-C. In turn, the IL-2 moiety of the fusion protein stimulates natural killer (NK) cells, macrophages and neutrophils and induces T-cell antitumor cellular immune responses thereby selectively killing tenascin-C-expressing tumor cells. In addition, F16-IL2 may potentiate the cytotoxicity of other chemotherapeutic agents. Tenascin-C, a glycoprotein of the extracellular matrix, is expressed in many cancer cell types. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/f16-il2-fusion-protein)
Mechanisms of Action: NK Cells
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Philogen
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Carcinoma, Merkel Cell|Breast Cancer|Melanoma|Non-Small-Cell Lung Cancer
Phase 1: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2024 |
PubMed |
The role of TNC in atherosclerosis and drug development opportunities. |
|
01/01/2024 |
PubMed |
Clinical advances in TNC delivery vectors and their conjugate agents. |
|
06/28/2022 |
PubMed |
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. |
|
03/26/2021 |
News Article |
Immunocytokines Markets, 2030 |
